Inspire Medical Systems, Inc. (INSP)
USD 142.55
(0.44%)
USD 142.55
(0.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -160.69 Million USD | 62.86% |
| 2022 | -432.72 Million USD | -139.49% |
| 2021 | -180.68 Million USD | -13.01% |
| 2020 | -159.88 Million USD | -9720.1% |
| 2019 | 1.66 Million USD | 102.3% |
| 2018 | -72.36 Million USD | -1064.18% |
| 2017 | 7.5 Million USD | -16.67% |
| 2016 | 9 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -150.91 Million USD | 6.08% |
| 2024 Q2 | -163.52 Million USD | -8.35% |
| 2024 Q3 | -122.29 Million USD | 25.28% |
| 2023 FY | -160.69 Million USD | 62.86% |
| 2023 Q3 | -304.72 Million USD | 31.32% |
| 2023 Q2 | -443.68 Million USD | -2.01% |
| 2023 Q1 | -434.94 Million USD | -0.51% |
| 2023 Q4 | -160.69 Million USD | 47.27% |
| 2022 Q1 | -169.01 Million USD | 6.46% |
| 2022 Q4 | -432.72 Million USD | -5.88% |
| 2022 FY | -432.72 Million USD | -139.49% |
| 2022 Q3 | -408.67 Million USD | -163.27% |
| 2022 Q2 | -155.22 Million USD | 8.16% |
| 2021 Q1 | -151.58 Million USD | 5.19% |
| 2021 FY | -180.68 Million USD | -13.01% |
| 2021 Q4 | -180.68 Million USD | -0.85% |
| 2021 Q3 | -179.16 Million USD | -23.02% |
| 2021 Q2 | -145.64 Million USD | 3.92% |
| 2020 Q4 | -159.88 Million USD | -3.87% |
| 2020 Q1 | -50.95 Million USD | -3165.94% |
| 2020 FY | -159.88 Million USD | -9720.1% |
| 2020 Q2 | -186.26 Million USD | -265.54% |
| 2020 Q3 | -153.93 Million USD | 17.36% |
| 2019 Q1 | -77.58 Million USD | -7.21% |
| 2019 FY | 1.66 Million USD | 102.3% |
| 2019 Q4 | 1.66 Million USD | 107.05% |
| 2019 Q3 | -23.57 Million USD | 12.2% |
| 2019 Q2 | -26.85 Million USD | 65.39% |
| 2018 Q3 | -1.49 Million USD | 98.46% |
| 2018 FY | -72.36 Million USD | -1064.18% |
| 2018 Q2 | -97.15 Million USD | -823.76% |
| 2018 Q1 | 13.42 Million USD | 78.87% |
| 2018 Q4 | -72.36 Million USD | -4730.57% |
| 2017 Q1 | 6.68 Million USD | 0.0% |
| 2017 Q4 | 7.5 Million USD | 0.0% |
| 2017 FY | 7.5 Million USD | -16.67% |
| 2016 FY | 9 Million USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 101.79% |
| Allurion Technologies Inc. | 3.82 Million USD | 4306.571% |
| Artivion, Inc. | 300.4 Million USD | 153.492% |
| Avanos Medical, Inc. | 121.4 Million USD | 232.365% |
| Butterfly Network, Inc. | -109.6 Million USD | -46.604% |
| Butterfly Network, Inc. | -109.6 Million USD | -46.604% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 116.038% |
| Boston Scientific Corporation | 8.62 Billion USD | 101.863% |
| CONMED Corporation | 966.95 Million USD | 116.618% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 64.219% |
| Paragon 28, Inc. | 36.39 Million USD | 541.568% |
| Glaukos Corporation | 290.27 Million USD | 155.359% |
| Globus Medical, Inc. | 53.11 Million USD | 402.551% |
| Integer Holdings Corporation | 1.01 Billion USD | 115.796% |
| Medtronic plc | 24.76 Billion USD | 100.649% |
| Myomo, Inc. | -6.27 Million USD | -2462.854% |
| Nevro Corp. | 117.61 Million USD | 236.63% |
| Owlet, Inc. | -1.34 Million USD | -11882.932% |
| Penumbra, Inc. | 66.85 Million USD | 340.35% |
| Vicarious Surgical Inc. | -37.99 Million USD | -322.982% |
| Smith & Nephew plc | 2.78 Billion USD | 105.776% |
| Sonendo, Inc. | 26.34 Million USD | 710.018% |
| STERIS plc | 3.17 Billion USD | 105.059% |
| Stryker Corporation | 10.02 Billion USD | 101.603% |
| Vapotherm, Inc. | 102.66 Million USD | 256.517% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 102.88% |